Mission Therapeutics

Mission Therapeutics is a private, drug discovery and development company based in the United Kingdom, founded in 2011. The company is dedicated to selectively targeting deubiquitylating enzymes to address diseases with high unmet medical needs. Mission has succeeded in building a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). This innovative approach is gaining significant commercial interest and is considered as the potential 'Next Kinase Area.' The company's strategic emphasis lies in advancing its pipeline programs through early clinical development, with a preference for a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission's leadership team brings a wealth of international, commercial, and scientific experience, and the company has fostered strong collaborations with key academic and research centers such as Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. Mission Therapeutics has received a total of £87 million in venture capital from a prestigious syndicate including institutional and corporate investors. Additionally, the company was granted £1.9 million from Innovate UK in September 2015. In February 2016, Mission raised £60 million in a Series C financing round led by Imperial Innovations and new investor Woodford Patient Capital Trust, with follow-on investments from existing shareholders including Sofinnova Partners, SR One, Roche Venture Fund, and Pfizer Venture Investments. The company continues to make notable progress and is located at the Babraham Research Campus, south of Cambridge. Mission Therapeutics is primed to make a significant impact across biotechnology and healthcare sectors with its rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas.